MX2022014734A - Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. - Google Patents
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.Info
- Publication number
- MX2022014734A MX2022014734A MX2022014734A MX2022014734A MX2022014734A MX 2022014734 A MX2022014734 A MX 2022014734A MX 2022014734 A MX2022014734 A MX 2022014734A MX 2022014734 A MX2022014734 A MX 2022014734A MX 2022014734 A MX2022014734 A MX 2022014734A
- Authority
- MX
- Mexico
- Prior art keywords
- cervical cancer
- patient
- cemiplimab
- administering
- methods
- Prior art date
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title abstract 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title abstract 4
- 201000010881 cervical cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 229940121420 cemiplimab Drugs 0.000 title abstract 2
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona métodos para tratar, reducir la gravedad o inhibir el crecimiento de un tumor o mejorar la supervivencia general en una paciente con cáncer de cuello uterino, en donde el método incluye seleccionar un paciente con cáncer de cuello uterino que lo necesite y administrar al paciente una cantidad terapéuticamente eficaz de un inhibidor de muerte programada 1 (PD-1) (por ejemplo, un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del mismo, tal como cemiplimab o un bioequivalente del mismo). En ciertas modalidades, el paciente tiene cáncer de cuello uterino metastásico o recurrente con progresión de la enfermedad durante o después de la quimioterapia.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029757P | 2020-05-26 | 2020-05-26 | |
| US202063069942P | 2020-08-25 | 2020-08-25 | |
| US202163160074P | 2021-03-12 | 2021-03-12 | |
| US202163174474P | 2021-04-13 | 2021-04-13 | |
| US202163181434P | 2021-04-29 | 2021-04-29 | |
| US202163185881P | 2021-05-07 | 2021-05-07 | |
| PCT/US2021/034000 WO2021242728A1 (en) | 2020-05-26 | 2021-05-25 | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014734A true MX2022014734A (es) | 2023-03-15 |
Family
ID=76859703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014734A MX2022014734A (es) | 2020-05-26 | 2021-05-25 | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210403567A1 (es) |
| EP (1) | EP4157464A1 (es) |
| JP (2) | JP7240512B2 (es) |
| KR (1) | KR20230015954A (es) |
| CN (1) | CN115666724A (es) |
| AU (1) | AU2021280245A1 (es) |
| CA (1) | CA3168738A1 (es) |
| IL (1) | IL298273A (es) |
| MX (1) | MX2022014734A (es) |
| TW (1) | TW202210098A (es) |
| WO (1) | WO2021242728A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240043560A1 (en) * | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2925551A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| ES2982109T3 (es) | 2008-09-26 | 2024-10-14 | Dana Farber Cancer Inst Inc | Anticuerpos anti PD-1, PD-L1 y PD-L2 humanos y usos de los mismos |
| SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| AR091220A1 (es) | 2012-05-31 | 2015-01-21 | Genentech Inc | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| EP3079772B1 (en) | 2013-12-10 | 2020-02-05 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SMT202100191T1 (it) * | 2014-02-21 | 2021-05-07 | Nektar Therapeutics | Agonisti selettivi per il-2rbeta in combinazione con un anticorpo anti.ctla-4 o un anticorpo anti-pd-1 |
| AU2015301126B2 (en) | 2014-08-05 | 2021-03-11 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| MY194225A (en) | 2015-03-13 | 2022-11-22 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| PL3439653T3 (pl) | 2016-04-07 | 2021-07-05 | Chemocentryx, Inc. | Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018276140A1 (en) * | 2017-06-01 | 2019-12-19 | Compugen Ltd. | Triple combination antibody therapies |
-
2021
- 2021-05-25 CN CN202180038141.0A patent/CN115666724A/zh active Pending
- 2021-05-25 EP EP21740277.5A patent/EP4157464A1/en active Pending
- 2021-05-25 US US17/329,545 patent/US20210403567A1/en active Pending
- 2021-05-25 IL IL298273A patent/IL298273A/en unknown
- 2021-05-25 AU AU2021280245A patent/AU2021280245A1/en active Pending
- 2021-05-25 JP JP2021545411A patent/JP7240512B2/ja active Active
- 2021-05-25 CA CA3168738A patent/CA3168738A1/en active Pending
- 2021-05-25 TW TW110118832A patent/TW202210098A/zh unknown
- 2021-05-25 KR KR1020227044723A patent/KR20230015954A/ko active Search and Examination
- 2021-05-25 WO PCT/US2021/034000 patent/WO2021242728A1/en unknown
- 2021-05-25 MX MX2022014734A patent/MX2022014734A/es unknown
-
2022
- 2022-11-09 JP JP2022179201A patent/JP2023011902A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7240512B2 (ja) | 2023-03-15 |
| EP4157464A1 (en) | 2023-04-05 |
| CA3168738A1 (en) | 2021-12-02 |
| WO2021242728A1 (en) | 2021-12-02 |
| JP2023011902A (ja) | 2023-01-24 |
| CN115666724A (zh) | 2023-01-31 |
| US20210403567A1 (en) | 2021-12-30 |
| AU2021280245A1 (en) | 2022-12-08 |
| KR20230015954A (ko) | 2023-01-31 |
| IL298273A (en) | 2023-01-01 |
| TW202210098A (zh) | 2022-03-16 |
| JP2022530599A (ja) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4175951T3 (fi) | Hpk1-estäjiä ja niiden käyttötapoja | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| JP2019519499A5 (es) | ||
| EP4424712A3 (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2023000589A (es) | Terapia de combinacion para tratar el crecimiento celular anormal. | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| MX2021010228A (es) | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. | |
| MX2022010860A (es) | Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1. | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| MX2022014734A (es) | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. | |
| EP4382168A3 (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| MX2021006210A (es) | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
| MX2021009533A (es) | Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo. | |
| MX2023002123A (es) | Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1. | |
| MX2024008055A (es) | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. |